intramuscularly or subcutaneously. Additional doses should be based on patient response. The intravenous route may be used if an immediate response is required. The dosage for the intravenous route is 10 to 25 mg which may be repeated every 5 to 10 minute until the desired response is obtained. Paediatric dose: The recommended paediatric dose is 3 mg/kg/day or 100 mg/m2/day via the intravenous or subcutaneous route, given in 4 to 6 divided doses. During therapy with a pressor agent, blood pressure should be elevated to slightly less than the patient’s normal blood pressure. In previously normotensive patients, systolic blood pressure should be maintained at 80 to 100 mmHg. In previously hypertensive patients, systolic blood pressure should be maintained at 30 to 40 mmHg below their usual blood pressure. In some patients with very severe hypotension, maintenance of even lower blood pressure may be desirable if blood or fluid volume replacement has not been completed. Bronchospasm: dose: The usual adult dose is 12.5 to 25 mg, given intramuscularly, subcutaneously or intravenously. Further dosage should be determined by patient’s response. Paediatric dose: The usual paediatric dose is 3 mg/kg/day or 100 mg/m2/day via the intravenous or minute until the desired response is obtained. Paediatric dose: The recommended paediatric dose is 3 mg/kg/day or 100 mg/m2/day via the intravenous route, given in 4 to 6 divided doses. During therapy with a pressor agent, blood pressure should be elevated to slightly less than the patient’s normal blood pressure. In previously normotensive patients, systolic blood pressure should be maintained at 80 to 100 mmHg. In previously hypertensive patients, systolic blood pressure should be maintained at 30 to 40 mmHg below their usual blood pressure. In some patients with very severe hypotension, maintenance of even lower blood pressure may be desirable if blood or fluid volume replacement has not been completed.
Dosage Adult and the elderly Up to 30 mg in increments of 3 to 7.5 mg. After the development of hypotension, by slow intravenous administration. Children 0.5 to 0.75 mg / kg body weight or 17 25 mg / m2 body surface. After the development of hypotension, by slow intravenous administration. As a pressor IM or SC adults 25 to 50 mg, additional doses based on response. IV adults 10 to 25 mg repeated every 5 to 10 minutes. Paediatric 3 mg/kg/day or 100 mg/m2/day IV or SC, given in 4 to 6 divided doses. Bronchospasm IV, IM or SC adults 12.5 to 25 mg, additional doses based on response. Paediatric 3 mg/kg/day or 100 mg/m2/day IV or SC, given in 4 to 6 divided doses. As a pressor IM or SC adults 25 to 50 mg, additional doses based on response. IV adults 10 to 25 mg repeated 5 to 10 minutes. Paediatric 3 mg/kg/day or 100 mg/m2/day IV or SC, given in 4 to 6 divided doses. Bronchospasm IV, IM or SC adults 12.5 to 25 mg, additional doses based on response. Paediatric 3 mg/kg or 100 mg/m2 IV or SC, given in 4 to 6 divided doses. As a pressor Adults 10 to 25 mg IV repeated 5 to 10 minutes. Paediatric 3 mg/kg/day or 100 mg/m2/day IV, given in 4 to 6 divided doses. We believe that the SCP Ephedrine hydrochloride injection is a safe and efficacious alternative to the current sulfate formulation, when used according to the advice provided in the proposed PI. A clean and annotated copy of the proposed PI is provided.